PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of ascpBioMed CentralBiomed Central Web Sitesearchsubmit a manuscriptregisterthis articleAddiction Science & Clinical Practice
 
Addict Sci Clin Pract. 2010 December; 5(2): 62–63.
PMCID: PMC3120117

This Issue’s Authors

ELIZABETH ALONSO, Ph.D., is an assistant scientist at the Center for Family Studies (CFS) at the University of Miami. Since 2004, she has worked as a coordinator and trainer in clinical trials with substance-using populations and is currently the director of quality assurance at the CFS. She provides consultation, training, and oversight of monitoring activities on numerous studies.

KEN BACHRACH, Ph.D., is a licensed psychologist and the clinical director of Tarzana Treatment Centers (TTC), one of the largest providers of substance abuse and integrated behavioral health services to adults and youth in Southern California. He has over 25 years of experience in the treatment of chemically dependent individuals and those with co-occurring psychological disorders. He regularly trains substance abuse and mental health professionals in this area and coordinates TTC’s activities in NIDA’s Clinical Trials Network.

SAMUEL A. BALL, Ph.D., is a professor at Yale University School of Medicine in the Department of Psychiatry, where he also serves as the director of career development. He is also the director of research for The APT Foundation and for the NIDA-funded Resident/Intern Substance Use Research Education (REINSURE) and Building Interdisciplinary Research Careers in Women’s Health (BIRCWH) training programs at Yale. Dr. Ball’s major research interest involves the evaluation of personality dimensions and disorders as important constructs for predicting treatment outcomes and developing interventions for substance-dependent patients.

KATHY BURLEW, Ph.D., is a professor of psychology at the University of Cincinnati and a member of the State Board of Psychology in Columbus, Ohio. Dr. Burlew is a former editor of the Journal of Black Psychology. Her publications include four books and several articles on substance abuse treatment and prevention. In 2007, she received the University Excellence in Mentoring Award and the Distinguished Teaching Award from the University of Cincinnati.

IBIS S. CARRIÓN, Psy.D., is a clinical consultant and the NIDA liaison coordinator of the Caribbean Basin & Hispanic Addiction Technology Transfer Center in the Institute of Research, Education and Services in Addiction at the Universidad Central del Caribe School of Medicine in Bayamón, Puerto Rico. Dr. Carrión has over 13 years of experience in the substance abuse field, is a licensed psychologist in Puerto Rico, and is a member of the American Psychological Association.

THOMAS J. GOULD, Ph.D., is an associate professor of psychology at Temple University and head of the Neurobiological Investigations of Learning & Addiction (NILA) lab. He is also a member of the Temple University Neuroscience Program and an investigator and member of the Transdisciplinary Tobacco Use Research Center at the University of Pennsylvania. Dr. Gould is the author of more than 70 scholarly manuscripts. His current research interest is in the neurobiology of learning and memory, with a specific focus on identifying the cellular and molecular events that underlie the effects of nicotine and ethanol on cognition. This research also examines genetic factors that may contribute to the effects of nicotine on cognition.

CRAIG HENDERSON, Ph.D., is an assistant professor of psychology at Sam Houston State University. His research focuses on family psychology and addictive behaviors, particularly the treatment of adolescent substance abuse. The goal of his research is to strengthen family relationships of at-risk youth and to improve services for adolescents with substance abuse and associated problems. He also specializes in the application of advanced longitudinal statistical models to adolescent drug abuse research.

CANDACE C. HODGKINS, Ph.D., is a senior vice president of research for Gateway Community Services (GCS). She has more than 23 years of experience in the assessment and treatment of mental health and addiction disorders. She has been the principal investigator for eight federally funded grants for the Center for Substance Abuse Treatment of the Substance Abuse and Mental Health Services Administration and currently is GCS’s site principal investigator for all current protocols in NIDA’s Clinical Trials Network.

VIVIANA E. HORIGIAN, M.D., is a research assistant professor in the Department of Epidemiology and Public Health at the University of Miami’s Miller School of Medicine. Dr. Horigian has more than 11 years of experience in the implementation of clinical trials, including oversight of the Brief Strategic Family Therapy for Adolescent Drug Abuse effectiveness trial. Currently, she is the program director for the Florida Node of NIDA’s Clinical Trials Network.

STEVE MARTINO, Ph.D., is an associate professor of psychiatry at the Yale University School of Medicine. He specializes in the treatment of addictive disorders and of patients diagnosed with co-occurring psychiatric problems and has specific interests in motivational interviewing and cognitive-behavioral therapy. He also develops and investigates strategies for training community program clinicians in empirically supported treatments. Dr. Martino is the training director of the New England Node of NIDA’s Clinical Trials Network (CTN) and chair of the CTN Research Utilization Committee. In addition, Dr. Martino is the education director for the Yale Substance Abuse Treatment Psychotherapy Development Center and a member of the Motivational Interviewing Network of Trainers.

MICHAEL MILLER, Ph.D., has served The Village South, a substance abuse treatment facility in Miami, Florida, for the past 20 years in a variety of capacities. He directed two demonstration projects for the Center for Substance Abuse Treatment and was the site principal investigator for the Marijuana Treatment Project and two CTN clinical trials: Women and Trauma and Brief Strategic Family Therapy. He also trains community agencies in Motivational Interviewing Assessment: Supervisory Tools for Enhancing Proficiency (MIA:STEP).

MARGARET MROZIEWICZ, M.Sc., worked with Dr. Rachel Tyndale in the Department of Pharmacology and Toxicology at the University of Toronto as a graduate student. She studied the effect of genetic variation in nicotine metabolism on smoking cessation with nicotine patch therapy.

MICHAEL S. ROBBINS, Ph.D., is a scientist at the Oregon Research Institute and director of research at Functional Family Therapy, LLC. He has extensive experience conducting research on family therapy for adolescents with behavior problems. Dr. Robbins—a former research associate professor at the University of Miami’s Miller School of Medicine—serves as the master trainer for Brief Strategic Family Therapy, overseeing the training of hundreds of therapists nationally and internationally. He has published extensively in the areas of process and outcome research in adolescent drug abuse treatment.

ERIC SCHINDLER, Ph.D., is the chief executive officer of Child & Family Resources, Inc., an Arizona community nonprofit organization dedicated to building strong families, preventing child abuse, and promoting early childhood education. He coauthored the article on Brief Strategic Family Therapy while he was the senior clinical administrator at La Frontera Center, a community behavioral health care organization providing integrated mental health and substance abuse treatment and prevention services. He was the clinical treatment program principal investigator for NIDA CTN protocols at that site.

JODY L. SINDELAR, Ph.D., is a professor and chair of the Division of Health Policy and Administration, Yale School of Public Health, and has an appointment at the Institution for Social and Policy Studies at Yale. She is also a research associate at the National Bureau of Economic Research in Cambridge, Massachusetts. Dr. Sindelar is immediate past president of the American Society of Health Economists. Her expertise is in the economics of substance abuse, including cost-effectiveness of treatments, behavioral economics, policy evaluations, and social costs. She has been principal investigator on a number of large National Institutes of Health grants. Her research has been published in economics, addiction, and policy journals, and she serves on several advisory and editorial boards.

JOSÉ SZAPOCZNIK, Ph.D., is a professor and chair of the Department of Epidemiology and Public Health, associate dean for community development, and director of the Center for Family Studies at the University of Miami’s Miller School of Medicine. The recipient of numerous NIH research grants and author of many scholarly publications, he has been appointed to the national advisory councils for NIDA, the National Institute of Mental Health, the NIH AIDS Program Advisory Committee, and the Center for Substance Abuse Prevention.

RACHEL F. TYNDALE, Ph.D., is the Canada Research Chair in Pharmacogenetics and a professor in the departments of Psychiatry and of Pharmacology and Toxicology at the University of Toronto. She is also the pharmacogenetics section head at the Centre for Addiction and Mental Health in Toronto and vice-chair of the NIH Pharmacogenomics Research Network. Dr. Tyndale’s research focuses on pharmacogenetic variation in drug-metabolizing enzymes and their targets in the brain and the resulting impact on substance dependence and treatment, in particular smoking. Her team also studies the regulation and expression of these enzymes in the brain and their role in drug response and neurotoxicity. Dr. Tyndale is on a number of editorial boards and is an associate editor for Clinical Pharmacology & Therapeutics. She has published more than 150 papers and has 10 active grants.

NANCY VanDeMARK, Ph.D., has worked as an administrator, clinician, and researcher in the substance abuse field since 1982. She formerly worked for Arapahoe House, a substance abuse treatment provider in Colorado, and is currently a consultant assisting state and local agencies with program development, implementation, and evaluation.

& PANEL RESPONDENTS

GREG BRIGHAM, Ph.D., is chief research officer at Maryhaven, a substance abuse treatment facility in Columbus, Ohio, and a research scientist at the University of Cincinnati. Dr. Brigham has specialized in addiction treatment and prevention since 1982. He has developed and implemented a wide range of behavioral and medication-assisted treatment programs. He is active in local, State, and national efforts for the adoption of evidence-based practices and has participated in the development and implementation of numerous clinical trials of community-based substance abuse treatments.

CARRIE DODRILL, Ph.D., is an assistant professor and staff psychologist at the Michael E. Debakey Veterans Affairs Medical Center at Baylor College of Medicine. She also is a member of the Motivational Interviewing Network of Trainers. Dr. Dodrill’s experience includes roles in several randomized controlled trials funded by the National Institutes of Health, the Centers for Disease Control and Prevention, and the Health Resources and Services Administration. She is currently involved in studies to reduce environmental tobacco smoke in the homes of infants who received neonatal intensive care, to use expressive writing as an intervention for depressed clients court-referred for alcohol and drug treatment, and to increase management of opioid addiction by using buprenorphine in primary care.

VITKA EISEN, Ed.D., M.S.W., is chief executive officer for Walden House, Inc., in San Francisco, one of the largest providers of behavioral health care to poor and uninsured Californians. She oversees Walden House’s network of substance abuse and mental health treatment, re-entry, and prevention services throughout California for incarcerated men and women, ex-offenders, and other substance abusers and their families in the community. Dr. Eisen has served on the faculty of San Francisco State University’s School of Social Work and Porterville Community College. She has over 20 years of experience in the human services field and a lifelong commitment to supporting people struggling with addiction and incarceration.

RON JACKSON, M.S.W., is the executive director of Evergreen Treatment Services (ETS), a private non-profit organization in Seattle, Washington, that provides outpatient opioid treatment to more than 1,500 patients in clinics in Seattle and Olympia. Mr. Jackson has investigated various types of interventions for individuals dependent on opiates, cocaine, and marijuana. He is currently a co-principal investigator for the Pacific Northwest Node of NIDA’s Clinical Trials Network and is an affiliate professor at the University of Washington’s School of Social Work.

MICHAEL LEVY, Ph.D., is the director of clinical treatment services at CAB Health & Recovery Services, an organization that offers a full continuum of care for clients with substance use disorders. Dr. Levy has written numerous articles and book chapters and has given many workshops that focus on working with clients with substance use disorders and those with co-occurring disorders. In 2007 he published the book, Take Control of Your Drinking … And You May Not Need to Quit.

MICHAEL S. SHOPSHIRE, Ph.D., is quality assurance and regulatory affairs coordinator for the California-Arizona (CA-AZ) Node of the NIDA Clinical Trials Network at the University of California, San Francisco. He is co-author of Anger Management for Substance Abuse and Mental Health Clients: A Cognitive-Behavioral Therapy Manual, which has been widely disseminated by the Center for Substance Abuse Treatment. Dr. Shopshire actively works to disseminate NIDA/SAMHSA Blending Initiative products to community treatment programs affiliated with the CA-AZ Node, and he is particularly interested in evaluating and disseminating evidence-based substance abuse treatments for racial and ethnic minorities.

JOHN WANNER, M.A., L.C.A.D.C., is a counselor at Father Martin’s Ashley, Inc., an alcohol and drug treatment facility near Havre de Grace, Maryland. He also teaches courses in addiction counseling at the Community College of Baltimore County. Mr. Wanner has 15 years of counseling experience in inpatient and outpatient settings, addressing all aspects of patients’ substance abuse problems by using a combination of psychodynamic and cognitive-behavioral therapy. He has established a program tailored to the addiction problems of young adults.

JANET WOOD, M.B.A., M.Ed., is director of the Division of Behavioral Health within the Colorado Department of Human Services. Ms. Wood serves as both the single-State authority for substance abuse and the mental health commissioner for Colorado. She was a former presidential appointee to the White House Advisory Commission on Drug-Free Communities, served for 3 years as a member of the National Advisory Council on Drug Abuse, and serves as vice-chair for treatment on the Colorado Attorney General’s State Methamphetamine Task Force. She has 30 years of experience in human services management, 20 of which she served in State Government.


Articles from Addiction Science & Clinical Practice are provided here courtesy of BioMed Central